Can ACE Inhibitors and Angiotensin Receptor Blockers Be Detrimental in CKD Patients?

Macaulay A.C. Onuigbo

College of Medicine, Mayo Health System Practice-Based Research Network, Mayo Clinic, Rochester, Minn., and Department of Nephrology, Midelfort Clinic, Mayo Health System, Eau Claire, Wisc., USA

Key Words
Acute kidney injury • Angiotensin-converting enzyme inhibitors • Angiotensin receptor blockers • Chronic kidney disease • End-stage renal disease • Late-onset renal failure from angiotensin blockade • Renoprotection • Renoprevention • Syndrome of rapid-onset end-stage renal disease

Abstract
Current epidemiological data from the USA, Europe, Asia and the Indian subcontinent, Africa, the Far East, South America, the Middle East and Eastern Europe all point to the increasing incidence of renal failure encompassing acute kidney injury (AKI), chronic kidney disease (CKD) and end-stage renal disease (ESRD). While the explanations for these worldwide epidemics remain speculative, it must be acknowledged that these increases in AKI, CKD and ESRD, happening worldwide, have occurred despite the universal application of strategies of renoprotection over the last 2 decades, more especially the widespread use of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). We note that many of the published large renin-angiotensin-aldosterone system (RAAS) blockade randomized controlled trials, upon which current evidence-based practice for the increasing use of ACEIs and ARBs for renoprotection derived from, have strong deficiencies that have been highlighted over the years. From reports in the literature, there is an increasing association of exacerbations of renal failure with ACEIs and ARBs, more so in the older hypertensive patient, >65 years old. The biological plausibility for ACEI and ARB to protect the kidneys against a background of potential multiple pathogenetic pathways to account for CKD progression appears to be not very defensible. We reviewed the literature along these lines and submit that ACEIs and ARBs often cause unrecognized significant worsening renal failure in CKD patients, sometimes irreversible, and that more caution is required regarding their use, especially in the older hypertensive patients, with likely ischemic hypertensive nephropathy. Given the increasing association of concomitant RAAS blockade with worsening renal failure following exposure to iodinated contrast, during acute illness, in the perioperative period and following lower bowel preparations prior to colonoscopy, we submit that, preferably, ACEIs and ARBs be withheld for 2–4 days prior to or during these clinical scenarios. This represents the concept of renoprevention.
Introduction – The Renal Failure Epidemic around the World Continues

Current epidemiological data from the USA, Europe, Asia and the Indian subcontinent, Africa, the Far East, South America, the Middle East and Eastern Europe all point to the increasing incidence of renal failure encompassing acute kidney injury (AKI), chronic kidney disease (CKD) and end-stage renal disease (ESRD) [1–18]. According to ESRD statistics released by the United States Renal Data System in October 2010, the prevalent ESRD population in the USA reached an all-time high of 547,982 as of December ending 2008 [19]. This represented a 1.2% jump from 2007, compared to a 0.85% increase from 2006 to 2007 [19]. The argument by some authorities that the prevalence of ESRD in the USA is rising but only due to increased survival of patients with ESRD is not valid since the incident ESRD population for 2007 was 108,335 compared to a higher incidence value of 112,476 in 2008 [19]. Besides, in the USA, between 1996 and 2003, the incidence of nondialysis requiring community-based AKI increased from 322.7/100,000 to 522.4/100,000 person-years [20]. Equally, the incidence of dialysis-requiring AKI increased from 19.5/100,000 to 29.5/100,000 person-years [20]. Hospital incidence for AKI per 10,000 population in the USA increased from 1.8 in 1980 to a shocking 36.5 in 2005 [21]. Simultaneously, in 2008, a US Centers for Disease Control and Prevention report showed an acceleration of CKD prevalence up to 16.5% among the US population aged ≥20 years in the period 1999–2004, representing a 15.9% increase in CKD prevalence when compared to the 1988–1994 period [22]. Across Africa, several recent reports have described ESRD rates increasing by 75% between 2000 and 2004 [23], CKD accounting for nearly 10% of hospital admissions [24, 25], renal outpatient visits representing nearly 25% of all medical outpatient attendance and deaths from renal disease accounting for over 20% of all medical deaths [15]. Furthermore, from Eastern Europe, the same picture of an increasing ESRD population continues to unfold [9, 26]. In Romania, Eastern Europe, national statistics from 2003 showed that ESRD and renal replacement therapy (RRT) incidence had increased to 128 per million population with a prevalence of 250 per million population, and these numbers represented 500% and 600% increases, respectively, compared to figures from 1996 [26]. A previous report from the same group had revealed that in 1995, only one third of the patients needing RRT could be treated then in Romania [9]. With an increase in the number of available dialysis units in Romania, mostly continuous ambulatory peritoneal dialysis units, the RRT coverage for patients with ESRD in the Eastern European country had improved very dramatically, when compared to the mid 1990s [26]. Additionally, recent ESRD Registry data from the UK show that there were 45,484 patients receiving RRT by December 31, 2007, and this represented an annual growth rate of 5% for patients receiving RRT, according to 2009 published data [18].

While the explanations for these worldwide epidemics remain speculative, it must be acknowledged that these increases in AKI, CKD and ESRD, happening worldwide, have occurred despite the universal application of strategies of renoprotection over the last 2 decades, especially the widespread use of angiotensin-converting enzyme (ACE) inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) [27–36].

Mechanisms of CKD Progression Still Remain Uncertain

The mechanisms underlying the development of albuminuria in diabetic nephropathy remain controversial and continue to be vigorously debated [37, 38]. The exact anatomical site of the damage to the kidneys that relates to the poor renal outcomes in diabetic nephropathy is also questionable [37, 38]. As recently as 2009, new published experimental evidence suggests that, in fact, tubular dysfunction constituted the primary factor in the causation of early albuminuria from diabetic nephropathy as against a glomerular origin, the latter presumption being the more traditional consensus [37, 38]. Furthermore, the culprit pathogenetic molecule responsible for the initiation and propagation diabetic nephropathy remains unproven and uncertain [39–53]. Several independent and often conflicting lines of evidence from both human and experimental studies point to a variety of different pathogenetic mechanisms including oxidative stress, underlying genetic predispositions such as the nonmuscle myosin heavy-chain 9 gene on chromosome 22 or variants at chromosome 6q24–27 among African Americans [39–42], the production of advanced glycosylation end-products and the interaction of these end-products on the multiligand receptor of the immunoglobulin superfamily receptor for advanced glycation end-products [43, 44], a role for intrarenal angiotensin II and/or renin production [45], pathogenetic roles for inflammation [46], lipid toxicity [47, 49], podocyte injury and apoptosis [50, 51], and chemokine/growth factor release causing renal injury [52, 53].
Moreover, the prevailing consensus among nephrologists and internists is the commonly accepted archetype of a predictable and orchestrated progression of kidney involvement in diabetic nephropathy over the years, starting with a period of normoalbuminuria, then the inception of microalbuminuria with hyperfiltration, then the advancement to macroalbuminuria, then overt proteinuria, followed by a doubling of serum creatinine, and ultimately the subsequent progression to ESRD and need for RRT [54]. This model is significantly flawed, is not based on any established evidence and remains unproven [55, 56]. The proportion of CKD patients with diabetic nephropathy who progress so predictably and orderly along this predicted model remains unknown and unclear [56]. Indeed, Tsalamandris et al. [57] had followed 40 diabetic patients and demonstrated a complete disassociation between albumin excretion rates (AERs) and 24-hour creatinine glomerular filtration rate (GFR) values with time. During a 7-year follow-up, a progressive increase in AER was observed in 15 (38%) patients without any decline in GFR, a progressive increase in AER concurrent with decreasing GFR in 13 (33%) patients, consistent with the archetypal pattern of diabetic nephropathy, and another group of 12 (30%) patients demonstrated decreasing GFR without any significant increase in AER [57]. Despite these drawbacks and uncertainties, much of the evidence base supporting the use of renin-angiotensin-aldosterone system (RAAS) blockade for renoprotection derive from claims of antiproteinuric effects of ACEIs and ARBs.

Furthermore, there is significant uncertainty about the natural history of CKD, in general as current literature on ESRD rates and mortality rates in CKD remains conflicting, nonuniform and even controversial [58–60]. Different reports have demonstrated widely dissimilar and varying ESRD and mortality rates among CKD patients [58–60]. We cannot agree more with Bansal and Hsu [61], who in a recent review of the presentation and prognosis of CKD had emphasized on the heterogeneity of the CKD population and had concluded that CKD patient prognostication and management must be individualized [62].

From the foregoing, it is only fair to conclude that the pathogenetic mechanisms of the chronic nephropathies, CKD in general, hypertensive, diabetic and nondiabetic alike, remain mostly speculative and conjectural at this time, and therefore the hope or claims that any one specific treatment method targeting only one pathogenetic mechanism could successfully retard or reverse CKD progression can only, as of now, be tentative and provisional, but not proven. Also the natural history of CKD remains unclear, and a no-one-size-fits-all approach must be adopted for all CKD patients.

### A Brief Critique of the Evidence Base for Renoprotection with RAAS Blockade

Many of the published large RAAS blockade randomized controlled trials (RCTs), upon which current evidence-based practice for the increasing use of the ACEIs and ARBs for renoprotection derived from, have strong deficiencies that have been highlighted over the years [55, 56, 63–80]. These RCTs have several design flaws, and questions abound regarding the general applicability of the trial findings from these RCTs to the general CKD population, more so the older (>65-year-old) CKD patients [55, 56, 63–80]. The several limitations and concerns raised regarding the veracity of the claims of these RCTs as well as doubts regarding the general applicability of the recommendations of the large RAAS blockade RCTs to especially the older CKD patient population include the following:

- Several RAAS blockade RCTs were relatively short-term studies with some reported studies often as short as 8–12 weeks [81].
- The RAAS blockade RCTs often enrolled younger patients usually with well-preserved baseline renal function; notably, as an exception, we note here that the RENAAL and IDNT trials recruited patients with fairly advanced CKD with baseline serum creatinine of 1.9 and 1.7 mg/dl, respectively [64, 67].
- Most of the RCTs involved a middle-aged patient population with relatively few comorbid conditions, previous known exposure to ACEIs or ARBs, proven tolerance to maximum doses of these agents, and these were patients with well-established drug adherence.
- Claims of renoprotection beyond blood pressure (BP) lowering have not been proven and are very doubtful as indeed a post hoc substudy analysis of the HOPE trial cohort had demonstrated that patients in the ramipril arm actually achieved significantly lower 24-hour BP levels compared to the placebo arm [82]. Also in other trials where BP-independent effects were claimed such as the RENAAL and IDNT trials, the treatment arms actually showed mean arterial BP values lower than placebo arms of as much as 3 mm Hg or more [64, 67]. Similarly, the patients in the combination arm of the ONTARGET trial demonstrated lower BP levels (2.4/1.4 mm Hg) throughout...
Furthermore, raising some serious doubts about the internal validity of the statistical analysis of such data with a very high likelihood of suffering from the phenomena of ecological fallacy and Simpson's paradox [56, 83–85]. Furthermore, there sometimes is excessive emphasis placed on the magnitudes of reduction of levels of proteinuria in the patients studied as definitive and proven renal end points, even though this premise of using proteinuria reduction as a therapeutic end point has never been validated in any studies [56, 77, 86].

Many of the RCTs contain statistical inconsistencies and apparent aberrations like the observation of substantial risk reductions in the doubling of serum creatinine and ESRD at the same time as a higher death rate in the losartan group versus placebo in the RENAAL study [64, 77].

In many of the RAAS blockade RCTs, trial drug(s) discontinuation rates have been unacceptably high. In the RENAAL trial, the trial drug was discontinued in 46.5% of patients on losartan versus a drug discontinuation rate of 53.5% in the placebo arm [64, 77]. The implications of these very high drug discontinuation rates in the RCT trials and the impact of these high study drug discontinuation rates on reported study outcomes and on statistical analysis can only remain hypothetical, and very open to strong debate and controversy among experts in the field.

The fact that despite the claims of many large RAAS blockade RCTs of a relatively high exclusion criterion for serum creatinine being set at >2.5 mg/dl, and the observation that the majority of these trials only ended up recruiting and studying patients with mean serum creatinine usually in the more normal 1.3–1.5 mg/dl range [55, 56, 72, 74, 77], raises some serious questions about the role of a selection bias for patients with preserved baseline renal function [55, 56, 77]. As a result, the extrapolation of many of the RCTs to the older CKD population is even more in doubt [55, 56, 72, 77].

As a final point, the RAAS blockade RCTs generally lacked strict systematic assessment methods, and were very deficient in the reporting of adverse events, thus raising concerns about safety issues including the underreporting of a potential nephrotoxicity of these agents [79].

Biologic Plausibility for Renoprotection with RAAS Blockade Questioned – The Absence of Proof of a Dose-Response Relationship between Increasing RAAS Blockade and the Achievement of Incremental Renal Benefits

As a result of the evidence recorded above, depicting the heterogeneity of the CKD population, the multiple pathways that potentially influence the initiation of, and the propagation of the chronic nephropathies, hypertensive, diabetic and non-diabetic, it is puzzling for the supposition that any one agent could then become the magic bullet in this area of medicine as some authorities would like to suggest the ACEIs and ARBs to be [55, 56]. Moreover, claims of BP-independent renoprotection by ACEIs and ARBs cannot be defensible following the report from Svensson et al. [82] cited earlier.

We must also note here that the rush to achieve total RAAS blockade in our patients is in antithesis to common sense physiology since the molecule angiotensin II does in fact have considerable physiological roles in the kidney and elsewhere in the body, both in health and in disease [87–89]. There is ample incontrovertible evidence for critically important physiological roles for angiotensin II, as an endocrine agent, in the orchestration of well-modulated and controlled renal glomerular and tubular transport systems [87]. Also, experimental evidence suggests that angiotensin II, acting through several genetic pathways, has crucial physiological roles in central tissue repair processes in the kidney, especially following renal injury [88, 89]. We would therefore argue that the concept of aggressive total RAAS blockade should not be pushed too far, beyond reason [55, 56].

Finally, if one were to assume that, indeed, all diabetic nephropathies were one homogenous entity and that all the pathogenetic derangements at play in the initiation and propagation of diabetic nephropathy were all secondary to the adverse consequences of angiotensin II overactivity, it stands to reason to expect a dose-response relationship between increasing RAAS blockade and improved effects of renoprotection in these patients. However, to the contrary, there is accruing evidence to date, in the literature, that posits that total RAAS blockade with combination ACEI + ARB or the use of supratherapeutic doses of ARBs have only resulted in worse renal outcomes, both in the short term, as shown in the report by Rossing et al. [90], and in the long term, as clearly evident in the results of the ONTARGET studies of over 25,000 patients [91, 92].
**Absence of Mortality Benefits in the RAAS Blockade Trials despite Purported Reduction in ESRD Rates**

Many RAAS blockade RCTs report statistically significant reductions of incident ESRD of up to 25% with follow-up [64, 65, 68, 69]. Crude annual mortality rates among US ESRD patients of 20% and over have been currently reported [93, 94]. One would therefore surmise that any therapeutic intervention that successfully and consistently reduced incident ESRD rates by as much as 25%, as claimed by the IDNT and RENAAL trials [64, 65, 69], should begin to demonstrate definite mortality benefits after only a few years of follow-up [55, 77]. Quite the opposite, one interesting and glaring statistical inconsistency that was revealed during our review of the RAAS RCTs was that despite the reported ESRD reductions in the ARB trials, quite often, after years of follow-up, there failed to be demonstrated any mortality benefits with RAAS blockade [55, 64, 65, 69, 77]. These apparent statistical aberrations are shown in table 1 and demand further explanation.

**The Association of AKI with RAAS Blockade in General**

In the last 5 years, we have published several reports from our single-center experience describing sometimes reversible AKI in CKD patients associated with concurrent RAAS blockade [55, 56, 71–76, 95]. The clinical circumstances under which we described worsening renal failure associated with concurrent RAAS blockade include the absence of any identifiable so-called precipitating risk factor [72], in association with multiple varied risk factors such as infections, heart failure exacerbation, hypotension and dehydration [70, 72], in association with renal artery stenosis [75, 76], in hospitalized patients [95], and in association with contrast-induced nephropathy [73, 96]. What is more, recently, sustained increases in estimated GFR (eGFR) were demonstrated from 16.4 to 26.6 ml/min/1.73 m² body surface area, in 52 patients, mean age 73 years, following the discontinuation of ACEIs and/or ARBs [97, 98]. Besides, previously in a Canadian study, Suissa et al. [78] had demonstrated in a population-based historical cohort analysis of 6,102 diabetic patients (mean age 66 years) an increased ratio of ESRD of 4.2 (95% CI 2.0–9.0), after 3 years or longer of ACE inhibition. As well, the CHARM trials revealed a higher rate of doubling of serum creatinine in 82 (6%) candesartan-treated versus 47 (4%) placebo-treated patients (p = 0.002) [99, 100]. Additionally, the ALLHAT study demonstrated that among the diabetics studied, more patients in the ACEI lisinopril group progressed to ESRD, when compared to the diuretic chlorthalidone group (25/1,563 vs. 26/2,755, p = 0.05, RR 1.74, 95% CI 1.00–3.01) [101, 102]. Furthermore, Jones et al. [8] in 2005, after a thorough analysis of the US ESRD population growth, concluded that there was an ESRD epidemic here in the USA, and that the pace of the US ESRD epidemic outpaced the growth of the diabetes mellitus epidemic. The authors had examined the time trends in the US ESRD population, the diabetes literature and had come to the conclusion that the recent US ESRD epidemic could be related to the increasing use of ACEIs and ARBs since the 1990s [8]. Finally, drug-induced AKI, including the use of ACEIs and ARBs, accounted for a rising proportion of AKI among patients in two Jordanian hospitals in a recent analysis from the Middle East [103]. These observations must be taken very seriously, and our previous call for

**Table 1. Mortality versus ESRD rates in some RAAS RCTs showing statistical aberrations**

<table>
<thead>
<tr>
<th>Trial (publication year)</th>
<th>Study size, n</th>
<th>Mean age years</th>
<th>Trial drug vs. placebo/other</th>
<th>Indication for trial drug</th>
<th>Follow-up months</th>
<th>Baseline mean serum creatinine, mg/dl</th>
<th>ESRD/dialysis rate trial drug vs. placebo/other, %</th>
<th>All-cause mortality trial drug vs. placebo/other, %</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>REIN</strong> (1999)</td>
<td>186</td>
<td>49.5</td>
<td>ramipril (99) vs. placebo (87)</td>
<td>renoprotection in nondiabetic CKD</td>
<td>1.9</td>
<td>9 vs. 20.7 (p = 0.04)</td>
<td>1 vs. 0 (p = 0.94, n.s.)</td>
<td></td>
</tr>
<tr>
<td><strong>IDNT</strong> (2001)</td>
<td>1,715</td>
<td>59</td>
<td>irbesartan (579) vs. amlodipine (567)</td>
<td>renoprotection in type 2 diabetes mellitus</td>
<td>31</td>
<td>1.7</td>
<td>14.2 vs. 18.3 (p = 0.07, n.s.)</td>
<td>15 vs. 14.6 (p = 0.9, n.s.)</td>
</tr>
<tr>
<td><strong>IDNT</strong> (2001)</td>
<td>1,715</td>
<td>59</td>
<td>irbesartan (579) vs. placebo (569)</td>
<td>renoprotection in type 2 diabetes mellitus</td>
<td>31</td>
<td>1.7</td>
<td>14.2 vs. 17.8 (p = 0.1, n.s.)</td>
<td>15 vs. 16.3 (p = 0.6, n.s.)</td>
</tr>
<tr>
<td><strong>RENAAL</strong> (2001)</td>
<td>1,513</td>
<td>60</td>
<td>losartan (751) vs. placebo (762)</td>
<td>renoprotection in type 2 diabetes mellitus</td>
<td>41</td>
<td>1.9</td>
<td>19.6 vs. 25.5 (p = 0.007)</td>
<td>21 vs. 20.3 (p = 0.8, n.s.)</td>
</tr>
</tbody>
</table>

*Are ACE Inhibitors Detrimental in CKD Patients?*
more circumspection in the use of these agents cannot be overemphasized [55, 56, 77]. It must be acknowledged that the ONTARGET trial demonstrated increased AKI requiring dialysis in the combination arm (0.8 vs. 0.6%), but overall, there was no demonstrable change in the rate of CKD progression between the 3 treatment arms and no evidence for increased ESRD [74, 86]. Finally, given the preponderance of diabetes among the hypertension population, with 100% of the RENAAL and IDNT patients being diabetics, 45% of the ALLHAT hypertensives and 38% of the ONTARGET patients were diabetics, whereas nearly 70% of the ONTARGET patients were hypertensives, it is clearly untenable to begin to try to distinguish between study effects among CKD patients, as to hypertensive CKD versus diabetic CKD [64, 67, 74, 86, 101].

**RAAS Blockade and AKI in Specific Clinical Syndromes**

*Exacerbation of Acute Renal Failure Caused by Contrast-Induced Nephropathy*

Several reports had demonstrated an association between concurrent use of ACEIs and ARBs and the exacerbation of contrast-induced nephropathy in CKD patients [73, 77, 96, 104–108]. However, a few reports propose the opposite view that simultaneously administered ACEIs offer improved kidney protection and limit the effects of contrast-induced nephropathy on the kidneys [109, 110]. The evidence in the literature, on the balance, is very much in favor of worse renal outcomes of contrast-induced nephropathy with concurrent RAAS blockade [73, 77, 96, 104–108]. According to a recent post hoc analysis from the Dialysis-versus-Diuresis trial involving 412 patients, the patients treated with RAAS blockade (ACEIs or ARB), before exposure to contrast developed significantly more contrast-induced nephropathy within 72 h [111]. Even after adjustment for confounding comorbidities, treatment with ACEI or ARB turned out to be an independent risk predictor for contrast-induced nephropathy (11.9 vs. 4.2%, \(p = 0.006\)) [111]. Multivariate analyses (logistic regression) identified RAAS blockade to be an independent predictor of contrast-induced nephropathy (OR 3.082, 95% CI 1.234–7.698, \(p = 0.016\)) [111]. Correspondingly, Komenda et al. [108] demonstrated improved renal outcomes when ACEIs were temporarily withheld from patients, 2 days before undergoing coronary angiography, when compared to historical controls.

The RCT reported by Gupta et al. [109] that concluded that the ACEI captopril was in fact renoprotective administered the first dose of the trial captopril 25 mg t.i.d. versus placebo, for 3 days, starting just 1 h prior to coronary angiography. Clearly, it would seem that this approach would not have allowed enough ACEI effect to be experienced by the drug recipients before being exposed to the contrast, and therefore arguably both placebo and captopril recipients may not have been different, after all. Other flaws and limitations with this study include the small study size and the fact that the one therapy that is known to influence the incidence of contrast-induced nephropathy which is periprocedural intravenous fluid hydration therapy, was not standardized and the different physicians in the study used whatever intravenous fluid hydration therapy they wanted for the study patients [109]. Our conclusion from a critical statistical review of the study is that the findings by Gupta et al. could easily be explained by inadequate randomization and by chance.

Another report by Rosenstock et al. [112] also suggested that the withholding of ACEIs and ARBs before contrast exposure did not alter renal outcomes. One major limitation of this study was the fact that the ACEIs or ARBs were withheld only 24 h prior to coronary angiography [112]. In patients with significant CKD, the knowledge of pharmacokinetics would argue that 24 h was not an adequate time for the effect of concurrent RAAS blockade to disappear following the drug discontinuation and before contrast administration [112]. We submit that this could have explained the failure of this study to demonstrate any renal benefits associated with the withholding of ACEI or ARB before contrast exposure, compared to patients who continued to take the ACEI or ARB throughout the study [113, 114]. On this same basis, we would argue that the Canadian study by Komenda et al. [108] where the ACEI or ARB was stopped for a longer time interval before coronary angiography was then able to demonstrate improved renal outcomes when compared to historical controls in whom concurrent ACEI/ARB therapy was continued uninterrupted through coronary angiography [113, 114].

*Exacerbation of Acute Renal Failure in the Perioperative Period*

A recent literature review revealed an increasing number of reports that have continued to implicate the concurrent use of ACEIs and/or ARBs in the causation and aggravation of AKI on CKD patients following certain specific common procedures [115–122]. These procedures include postoperative states such as following gastric bypass surgery [115], after cardiac surgery [118] and following the use of oral phosphate sodium preparations.
for lower bowel preparations [116, 117, 120–122] (table 2). In a study of 504 patients who underwent gastric bypass surgery, preoperative use of ACEIs or ARBs (OR 2.06; 95% CI 1.05–4.04) was associated with increased frequency of AKI [115]. Additionally, the perioperative use of ACEIs/ARBs has recently been demonstrated to be significantly associated with an increased risk for AKI after cardiac surgery in 2 tertiary medical centers in Buffalo, New York [118]. Based on these reports [115–122], and taken together with our single-center experiences, we have proposed that the prophylactic withholding of ACEIs and/or ARBs, during acute illness, in the perioperative period, and prior to contrast exposure, should become standard of care, to limit the impact of AKI in CKD patients [55, 56, 77]. We coined the term renoprevention to encompass these practices [55, 56].

### RAAS Blockade, Acute Renal Failure and Renal Artery Stenosis

The association of accelerated renal failure in CKD patients with renal artery stenosis (RAS), receiving ACEI or ARB, has been acknowledged for a long time and is well reported in the literature [123–131]. However, these mostly retrospective reports, small case series and individual case reports concluded that there was the necessary requirement for additional precipitating risk factors to result in AKI in patients with RAS on concurrent RAAS blockade [75, 76, 123–131]. Some of these risk factors included the use of diuretics and the coadministration of nonsteroidal anti-inflammatory drugs, the so-called triple whammy effect [132, 133]. These previous RAS studies had also implied the usual reversibility of the renal
failure following drug withdrawal [123–131]. Furthermore, these earlier studies proposed the necessity for bilateral RAS lesions to be present in patients with dual kidneys, or the presence of unilateral RAS lesions in patients with single functioning kidneys, to allow for the precipitation of worsening renal failure by concomitant RAAS blockade [123–131]. Nevertheless, this current model of RAS and renal failure and RAAS blockade does not take into account the existence of microvascular renal arteriolar narrowing, not demonstrable on MRA or conventional angiography, and only evident on renal biopsy first described by Raine in 1990 [134]. Such microvascular renal arteriolar narrowing is still capable of stimulating a state of enhanced angiotensin II production from the renal juxtaglomerular apparatus in the same way as large RAS lesions do [72, 134]. We therefore had coined the term microvascular RAS to describe this previously unrecognized phenomenon that would then explain the precipitation of AKI in patients with normal-appearing renal arteries on conventional angiography while concurrently on an ACEI or an ARB [72]. This is the pathophysiological basis for the classic presentation of our recently described new syndrome of late-onset renal failure from angiotensin blockade [72].

Critical Review of the Evidence Base for the Claims of a Relationship between the Levels of Proteinuria in CKD Patients and Efficacy of Renoprotection with RAAS Blockade

The most quoted references for the claims that RAAS blockade has been demonstrated to be useful in CKD patients with proteinuria in excess of 1 g/day is a series of meta-analyses carried out by the ACE Inhibition in Progressive Renal Disease Study Group (AIPRD Study Group) [77, 135–137]. A critical review of these meta-analyses reveals very striking deficiencies [77].

In the last decade, 3 meta-analyses of patient level data carried out by the AIPRD Study Group on a total of 11 previously randomized controlled trials have consistently concluded that ACE inhibition in 1,860 pooled non-diabetic patients remained beneficial after adjustment for BP and urine protein excretion (relative risk 0.67, 95% CI 0.53–0.84) but that this benefit was not apparent in patients with baseline proteinuria of <0.5 g/day [135–137]. A critical analysis of the AIPRD reports was made in our previous publication with the identification of several serious drawbacks in the meta-analyses including the following [77]:

- Two of the 11 analyzed studies were unpublished personal communications.
- The average age of the 1,860 pooled cohort was only 52 years.
- The mean duration of the studies was only 2.2 years.
- The cited studies generally utilized lower end doses of the various ACEIs.
- The methods and frequencies of measurement of proteinuria in the pooled 11 studies were disparate – 10 studies reported urine protein excretion as total 24-hour urine protein excretion, whereas 1 study performed dipstick urinalysis on untimed urine samples with results noted simply as either ‘positive’ or ‘negative’.
- There was no standardization of the protocol for BP measurements in the 11 pooled studies.

In spite of these limitations, the study authors were bold enough to make very significant scientific extrapolations with respect to the degree of proteinuria in relation to renal outcomes and response to ACE inhibition. Finally, all 1,860 patients were nondiabetics, and the extrapolation of such prognostications to diabetic CKD patients is essentially baseless [77]. Thus, claims of successful renoprotection with RAAS blockade in CKD patients with proteinuria >1 g/day remains speculative and indeed unproven [77]. What is more, criticisms of the ALLHAT studies for not measuring proteinuria and the ONTARGET study for recruiting patients of whom only 4% had macroalbuminuria and 13% had microalbuminuria and the citation of these as major drawbacks to data interpretation and extrapolation from the ALLHAT and ONTARGET trials are therefore not warranted, after all.

The Phenomenon of Syndrome of Rapid-Onset End-Stage Renal Disease and Implications for Renoprotection

We again recently described the previously unrecognized syndrome of rapid-onset end-stage renal disease (SORO-ESRD) among CKD patients whereby, due to new medical and/or surgical events, the ensuing AKI leads to a precipitous fall in eGFR in previously stable CKD patients, leading to rapid and irreversible ESRD requiring RRT [56, 138]. Larger multicenter studies are warranted to further study the impact of SORO-ESRD among ESRD populations around the world. We anticipate that the proposed new ASSESS-AKI study, the assessment, serial evaluation and subsequent sequelae of AKI study, that would enroll 1,100 adult CKD patients and 100 children.
undergoing cardiac surgery and prospectively follow CKD progression for 4 years, would further clarify the scope of SORO-ESRD among the US ESRD population [139]. If shown to be a significant contributor to the growth of the ESRD population, SORO-ESRD must then be taken into consideration in current discussions related to the concepts of renoprotection [55, 56, 138]. We would submit that this phenomenon of SORO-ESRD only adds more urgency to our previous calls for more renoprevention practices to reduce the incidence of AKI among CKD patients [55, 56, 138]. By renoprevention, we include the judicious avoidance of potential nephrotoxic agents such as the aminoglycosides to treat infections in CKD patients, the minimalization if not the total avoidance of the use of contrast in these patients together with periprocedural intravenous fluid hydration therapy as applicable, the prompt correction and treatment of hypovolemia and hypertensive states, the avoidance of hypotension during major surgical procedures, and, in our opinion most importantly, the temporary withholding for 2–4 days of ACEIs and ARBs, before major surgical operations, before contrast exposure and during any acute illnesses [55, 56, 77]. We hypothesize that these renoprevention measures would, from our experience, invariably reduce the incidence of AKI, lessen ESRD by reducing the incidence of SORO-ESRD events, reduce patient morbidity and mortality, and help save the increasingly scarce healthcare dollars both here in the USA and around the world [55, 56, 77, 95, 138].

Conclusion

We conclude that physicians and healthcare providers ought to use ACEIs and/or ARBs with caution, especially in the older patients aged >65 years. We must bear in mind that these older patients were generally never studied in any of the RAAS RCTs. Our experience in our single center is very revealing where, of the 100 CKD patients who showed often reversible AKI on CKD following the discontinuation of ACEIs and/or ARBs, 75% were aged over 65 years, 63% over 70 years, and 23% were indeed over 80 years old [72]. The experience from Sheffield, UK, where El Nahas and his group showed improved eGFR following the discontinuation of ACEI and/or ARB in 52 CKD patients with a mean age of 73 years, only further consolidates these concerns [97, 98]. These agents have to be used very sparingly in older patients and very close and indefinite monitoring of kidney function, at least every 2 months, is mandatory from our experience, and not just for the first 30 days following drug initiation [55, 72, 77]. A repeat serum creatinine assessment is justified a week or so following any dose increase in these agents [55, 72, 77]. In some clinical settings, sometimes daily monitoring of serum creatinine is again justified during acute illness, following contrast exposure and in the perioperative period. There should be no resistance to the thought of carrying out a trial discontinuation of the ACEI and/or ARB in any patient presenting with recent progressive loss of eGFR if this eGFR loss could not be explained otherwise [72]. No physician or healthcare provider hesitates to stop warfarin in a patient who is actively bleeding and could potentially die, irrespective of the indication(s) for the anticoagulation. In fact, we often have to correct the anticoagulation very quickly with the use of fresh frozen plasma infusions and the use of parenteral vitamin K injections. Correspondingly, no healthcare provider hesitates to stop an antihypertensive in a patient presenting with severe hypotension. We do not see any difference between these clinical scenarios and the necessity to discontinue the ACEI and/or the ARB in a CKD patient exhibiting unexplained progressive AKI on CKD which may terminate in irreversible ESRD and the need for RRT [72, 97, 98, 138]. The ‘Do no harm’ Hippocrates oath must not be vilified, after all. CKD management must be individualized, as no one size fits all. If SORO-ESRD is shown to be prevalent among the ESRD population, this would call for even more major paradigm shifts in our current approach to the management of CKD in general, and ESRD in particular.

Finally, we would conclude by invoking the words of Santiago Ramón y Cajal (1852–1934), the Spanish histologist, physician, pathologist and Nobel laureate, whose pioneering investigations of the microscopic structure of the brain were so original and influential that he is considered by many to be the greatest neuroscientist of all time. Santiago Ramón y Cajal wrote, inter alia: ‘In summary, there are no small problems. Problems that appear small are large problems that are not understood.’ We would submit that late-onset renal failure from angiotensin blockade, SORO-ESRD and other yet to be recognized clinical syndromes related to the natural history of CKD are not small problems. They only appear small to those who do not understand them.
References


Are ACE Inhibitors Detrimental in CKD Patients?

Nephron Clin Pract 2011;118:c407–c419

c417


84 Ameringer S, Serlin RC, Ward S: Simpson’s
85 Kunz R, Friedrich C, Wolbers M, Mann JF:
86 Thuraisingham RC, Yaqoob MM: Blood
87 Svensson P, de Faire U, Sleight P, Yusuf S, Os-
88 Mann JF, Schmieder RE, McQueen M, et al,
89 Cooper H, Patall EA: The relative benefits of
90 Rossing K, Jacobsen P, Pietrasszek L, Parv-
91 ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, et al: Telmisartan, ramirolpir, or both in patients at high risk for vascular
92 Onuigbo MA, Onuigbo NT: Use of ultra-
107 Cirir M, Toprak O, Yesil M, et al: Angioten-
108 Komenda P, Zalunardo N, Burnett S, et al: Con-
109 Gupta RK, Kapoor A, Tewari S, et al: Cap-
110 Dangas G, Jakovou I, Nikolaos E, et al: Con-

Onuigbo

Nephron Clin Pract 2011;118:c407–c419
Are ACE Inhibitors Detrimental in CKD Patients?

Nephron Clin Pract 2011;118:c407–c419